By Pamela Scherer McLeod, from the Volume XXVII No. 1 – January 6, 2020 issue
WHEN AN ANATOMIC PATHOLOGY GROUP CONSIDERS IMPLEMENTING digital pathology and whole-slide imaging (WSI) for primary diagnosis, it must identify and understand a range of challenges and opportunities.
“Every pathology group should start by considering how it will use the related technologies of a digital pathology (DP) system and whole-slide imaging,” said Liron Pantanowitz, MD, Vice Chair
By Joseph Burns, from the Volume XXVI No. 13 – September 23, 2019 issue
CEO SUMMARY: Now that the FDA has cleared two digital pathology systems for use in primary diagnosis, a growing number of pathology groups are taking up the question of whether and when they should adopt and use a digital pathology system and whole slide imaging. One pathologist with hands-on experience working with different digital pathology
By Joseph Burns, from the Volume XXVI No. 10 – July 22, 2019 issue
CEO SUMMARY: Implementation of digital pathology and whole-slide imaging systems in the United States lags behind that of other countries for two reasons. One is a more acute shortage of pathologists in those countries and the other is a less restrictive regulatory environment. In some locations outside the United States, pathologists have adopted fully-digital operations,
By Joseph Burns, from the Volume XXVI No. 10 – July 22, 2019 issue
CEO SUMMARY: In May, the FDA announced clearance for Leica Biosystems to market its Aperio AT2 DX System for clinical diagnosis in the United States. The Aperio AT2 DX System is intended for in vitro diagnostic use as an aid to pathologists reviewing and interpreting digital images of surgical pathology slides prepared from formalin-fixed paraffin
By Robert Michel, from the Volume XXVI No. 8 – June 10, 2019 issue
Digital pathology is coming in a big way to two regions in two different nations. In the United Kingdom, it was announced on May 30 that the North Tees and Hartlepool NHS Foundation in the north of England signed a five-year contract with Sectra of Linköping, Sweden. Sectra is to deliver a “regional digital pathology solution” in
By R. Lewis Dark, from the Volume XXVI No. 7 – May 20, 2019 issue
INTERESTING THINGS ARE UNFOLDING within the profession of anatomic pathology. If the adage of “follow the money” applies to understanding why things happen, then recent events support some surprising conclusions.
Take the news reported in this issue of The Dark Report that PathGroup of Nashville is acquiring Pathologists Bio-Medical Laboratories (PBML) of Dallas. That brings together two regional
By Robert Michel, from the Volume XXVI No. 6 – April 29, 2019 issue
Investor interest in digital pathology (DP) and the use of artificial intelligence (AI) to analyze digital pathology images seems to be at a fever pitch recently. In the last three weeks, investors poured almost $85 million of capital into just three digital pathology companies, as noted below. This activity may be a sign that certain DP
By Mary Van Doren, from the Volume XXV No. 18 – December 24, 2018 issue
CEO SUMMARY: This year’s list of the Top 10 Lab Industry Stories for 2018 is dominated by new directives from Medicare and private health insurers, as well as significant decisions by federal courts. Collectively, these developments create new compliance risks for all clinical laboratories and anatomic pathology groups. What is more notable about these top
By Joseph Burns, from the Volume XXV No. 18 – December 24, 2018 issue
TO SHORTEN THE TIME FOR CANCER DIAGNOSES, the United Kingdom’s National Health Service (NHS) will open five new digital pathology and imaging centers that will use artificial intelligence. The digital pathology and imaging centers will open in Coventry, Glasgow, Leeds, London, and Oxford.
Last month, the UK government announced that it will invest £50 million ($68.9
By Robert Michel, from the Volume XXV No. 18 – December 24, 2018 issue
CEO SUMMARY: This year’s list of the Top 10 Lab Industry Stories for 2018 is dominated by new directives from Medicare and private health insurers, as well as significant decisions by federal courts. Collectively, these developments create new compliance risks for all clinical laboratories and anatomic pathology groups. What is more notable about these top
